Evaluation of SARS-CoV2 antibody Rapid Diagnostic Test kits (RDTs) and Real Time-Polymerase Chain Reaction (Rt-PCR) for COVID-19 Diagnosis in Kaduna, Nigeria

Introduction

The outbreak of the new coronavirus (SARS-CoV-2/COVID-19) infection has spread to every continent of the globe, thus, forcing us to adapt to living with it. Since the emergence of this virus, there has been a lot of challenges in trying to curtail it, leading to a halt in all economic and social activities both locally and internationally. (Nicola et al, 2020).

The SARS-CoV-2 virus is highly contagious and spreads easily within populations. Factors that aids the spread of the virus include; population density, environment social culture (Kaushik et al, 2020). The Clinical presentations of COVID-19 range from asymptomatic/mild symptoms to severe illness leading to multiple organ failure and death. Mortality from the disease is associated with advanced age, immune-compromised states, and those with comorbidities. (Guan et al, 2020).

Currently, there are over 5million cases worldwide with∼340,000 deaths. In Nigeria, initial cases of COVID-19 were imported from other countries, however, with the advent of community transmission, there are 61,194 confirmed COVID-19 cases, 52,303 discharged and 1119 deaths as at 17/10/2020 (NCDC 2020). At the moment, there are no effective therapeutic strategies to treat COVID-19. Several drug therapies and vaccines are in different stages of clinical trials, however, none of these trials have given conclusive results yet. (Darrel, 2020; Ryan, 2020) Prevention and control strategies employed include; physical distancing, heightened personal and respiratory hygiene as well as prompt notification of the presence of ant case defining symptoms.

Since onset of this pandemic, schools and a lot of other social activities have come to a standstill. The big question is how long will this remain? Strategies towards gradual reopening of the society have to be developed. Testing for antibodies to the SARS-CoV-2 virus and determining the level of herd immunity is a viable strategy that will aid policy makers on deciding when to re-open societies. Despite the medical, social and economic ramification of this pandemic Nigeria in general and Kaduna State in particular relies on tests kits, reagents and other accessories produced in other countries. Best practices require that any new test kit be validated before use. This will ensure that the performance of these kits is assessed and informed-decisions are taken by policy and regulatory bodies. The COVID-19 is also associated with socioeconomic problems. There is fear of contagion of the infection among the populace; the concept of social distancing is not compatible with the Nigerian and African communal structure. The lockdown policy embarked on in many states of the Nigeria Federation is not without hardship on the populace despite economic palliative measures of the government. At some point, a decision has to be made on when to re-open the economy and allow normal activities to resume, however, there is no locally relevant data on community exposure to and recovery from SARS-CoV2 in Kaduna State. This gap that will limit policy decisions such as when to ease restrictions and allow for normal activities including social, economic and educational to recommence; as well as vaccination targets for vulnerable versus general population

In response to the rising COVID-19 pandemic, several diagnostic test manufacturers have developed rapid and easy to use test kits to facilitate testing both within and outside the laboratory. Among which are test kits for the detection of antibodies in blood samples. However, the WHO recommends the validation of these test kits in appropriate populations and settings. (WHO, 2020) This is to prevent false positive or negative categorization of people which may hinder disease control efforts.

The availability of a locally validated and adapted antibody test kit will improve the ease and access to a screening tool for point of care testing in primary, secondary and tertiary health care centres thereby, strengthening the local testing capacity for COVID-19. This will generally improve the ease of diagnosis/screening of COVID-19 in resource constrained settings. The detection of asymptomatic infections using a locally validated serological test kit will also improve community surveillance capacity, which will aid in decision making on measures to control the viral spread such as when to enforce quarantine or isolation.

The ability to detect the immune response using a rapid and reliable serology test has a huge advantage in the assessment of the viral spread in the population and the level of herd immunity. This study will shed more light in understanding the immune response to the virus in both immune-competent and immune-compromised individuals. The comparative advantage of utilization of the validated test kits for COVID-19 screening in the general community cannot be overemphasized. This will help policy makers and clinicians to pick up previously undiagnosed asymptomatic infected persons who might have recovered and developed antibodies and may serve as a reservoir for convalescence plasma to be utilized for those with severe infection as a form of passive immunity, in the absence of specific drug therapies or vaccines. The screening can also help measure and determine how the society gradually ease back to normalcy and the number of patients coming for voluntary testing as well as reduction in stigma, which are in accordance with the targets of Goal 3 of the Sustainable Development Goals (SDG). This pilot study therefore, seek to assessed and compare the performance of the SARS CoV2 antibody test and Real Time Polymerase Chain Reaction (Rt-PCR) in the diagnosis of COVID-19. (Elitza et al., 2020)

Materials and Methods

Results

Serum samples were tested from 521 persons 167 of whom were COVID-19 cases and 354 were healthy individuals. The mean age of the participants was 35.2± 15 years. Majority of the cases (42.5%) and healthy (39.0%) participants were less than 30 years of age. There were more male cases (60.5%) and male healthy participants (60.5%) than females.

Discussions

The present study evaluated a commercial rapid test for detection of SARS-CoV-2-specific IgM and IgG. For the evaluation, samples from COVID-19 cases were obtained during disease condition and previously confirmed by PCR, were used as the true positives. According to the manufacturer of the PCR test, the specificity had been evaluated and was found to be 100% (95% CI:94.20% to 100%) for both IgM and IgG, while the sensitivity evaluated on COVID-19 cases was 87.3% (95% CI: 80.40% to 92.0%) for both IgM and IgG. Our results showed an overall very low sensitivity of IgM (14.4%) and IgG (15.6%). A study carried out by Li et al. in China in contrast to our study findings reported an overall high testing sensitivity of 88.7% and 90.6% specificity. The specificity results for our study for IgM (92.9%) and IgG (98.6%) were higher than what was reported in Li et al study.

There were 25 false IgM positive samples and 5 false positive IgG results observed from the healthy participants. This indicates that a cross-reaction to another coronavirus might have taken place. Previous literature has documented the occurrence of serological cross-reactions between SARS-CoV and SARS-CoV-2 (Wan WY 2020). Globally there are some other types of coronaviruses that affect humans that are endemic or even occur as epidemics. These include the 229E, HKU1, NL63 and OC43 strains. The picture of significant false positivises observed in this study may possibly be due the cross reaction from a previous infection with one of the strains of those other viruses mentioned above. It cannot be said for certain the commonality of the corona viruses as the agents responsible for the flu, but it has been estimated that about 20% of cases of the flu could be as a result of the coronaviruses (Bende M, 1989). The specificity for IgG detection of the rapid test evaluated in this study was similar to what was reported in another study of an enzyme-linked immunosorbent assay (ELISA), which had a specificity 97.5% (Zhao R 2020). However, the sensitivity of our study was very low as compared with that of the ELISA which was also 97.5%. This study generally showed a poor sensitivity performance of antibody tests for both IgM and IgG. The negative predictive values for the rapid tests in this study were not very high, indicating that this rapid test would not be useful for detecting past infections and possible immunity. It is not known when infection occurred for individuals in this study. The timing of the development of SARS-CoV-2–specific antibodies is variable. The humoral response kinetics to SARS-CoV-2 infection have not been fully understood, however it has been shown that reactive IgA, IgM, and IgG antibodies have been detected as soon as 1 day after symptom onset (Guo, 2020). In other previous studies, the antibodies were detected 10 to 15 days after symptom onset. The median time to the development of total antibody, IgM, and IgG has been estimated as 11, 12, and 14 days, respectively (Zhao,2020; Wu F,2020). We also investigated the possible associations between IgM, IgG and PCR positivity and sociodemographic characteristics. The associations found were those between IgM and IgG status and gender. According to the previous studies, gender has not been shown to have significant association with antibodies to SARSCoV-2. A study conducted in Spain did not show any statistically significant association with presence of IgM and IgG antibodies to SARS-CoV-2 and gender (Garcia-Basteiro 2020). Another study conducted in the United States of America similarly did not find any association between the presence of IgM and IgG antibodies to SARS-CoV-2 and gender (Havers FP, 2020). In another study conducted by Zeng et al. among 331 patients confirmed SARS-CoV-2 infection, it was found that level of IgG antibody in mild, general and recovering patients did not show any difference between males and females. However, the average IgG antibody level in female patients tended to be higher than that of in male patients in severe infections. It was observed that in comparison to male patients, most of the female patients generated a relatively high level of SARS-CoV-2 IgG antibody in severe infection. It was also reported that, the generation of IgG antibody in the females tended to be stronger than the male patients in the early phase of the disease. There are inconsistent findings from various studies on the associations between gender and SARS-CoV-2 antibody positivity. It is necessary for additional studies to be carried out to explore further and validate the relationship between gender and SARS-CoV-2 antibody positivity.

Recommendation and Conclusion

Although rapid antibody test kit has been found to be simple, inexpensive and faster in assessing COVID-19 infection in Humans, the specificity and sensitivity of the Innovita test kit for detecting SARS-CoV2 antibody as claimed by the manufacturer need to be reevaluated. The Rt-PCR still remain the gold standard as recommended by WHO for the diagnosis of SARS CoV2 infection until a more specific, sensitive and reliable rapid test kit has been developed and recommended by WHO for use at point of entry, point of care and for general community mass screening program for COVID-19 antibody.

Conflict of Interest

The authors declare that they have no conflicting interest.